Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|February 12, 2021
Experience the Art of Science on Your Drug Development Project with Pfizer CentreOne®
Author(s)Pfizer CentreOne
Pfizer CentreOne® is a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Visit www.pfizercentreone.com.
Pfizer CentreOne has years of drug development experience and there are few challenges we haven’t faced. We leverage our development and tech transfer expertise to guide your product through milestones and overcome project challenges to take you further.
Worldwide, our sites have been developing and manufacturing Pfizer’s broad array of innovative molecules for decades, and this legacy helps ensure a successful collaboration with you:
- Over 90 new products in
Pfizer's drug development pipeline
- More than 400 tech transfers in various stages a year (2019)
- Regulatory experience supporting 60+ countries
We offer the knowledge, network, and expert legacy to act as your creative problem solver and collaborative partner on your drug development project.
We offer an expert suite of development and optimization services in formulation, clinical drug manufacturing, analytical testing, validation, and method development.
Access our wide-range of capabilities to support today’s therapeutic trends:
- Small molecule APIs
- Large molecule biologics
- Oral solids
- Sterile injectables
Pfizer CentreOne
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.